|
⚲
|
| Keyboard |
| David Mott | |
|---|---|
| Firm | NEA Management Company LLC |
| Address | c/o New Enterprise Associates 5425 Wisconsin Avenue, Suite 800 Chevy Chase, MD 20815 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| NEA Management Company LLC | |||||
| NEA BH SPV LP | 021-355891 | Executive Officer | 129.3 M of 129.3 M |
2.4 M | |
| New Enterprise Associates 17 LP | 021-333845 | Executive Officer | of 3,600.0 M |
4,507.4 M | |
| New Enterprise Associates 16 LP | 021-278594 | Executive Officer | of 3,000.0 M |
4,673.1 M | |
| NEA 15 Opportunity Fund LP | 021-238034 | Executive Officer | 350.0 M of 350.0 M |
1,754.8 M | |
| New Enterprise Associates 15 LP | 021-231999 | Executive Officer | of 2,500.0 M |
2,925.7 M | |
| New Enterprise Associates 14 LP | 021-175533 | Director | 2,075.9 M of 2,562.9 M |
7,761.5 M | |
| New Enterprise Associates 13 LP | 021-125476 | Director | 2,457.7 M of 2,500.0 M |
648.3 M | |
| Complexa Inc | 021-337393 | Director | 11.0 M of 28.0 M |
||
| Imara Inc | 021-336073 | Director | 44.1 M of 63.0 M |
||
| 3-V Biosciences Inc | 021-333505 | Director | 35.2 M of 42.2 M |
||
| Tiburio Therapeutics Inc | 021-329946 | Director | 5.0 M of 31.0 M |
||
| Cydan II Inc | 021-296407 | Director | 10.7 M of 34.0 M |
||
| Complexa Inc | 021-291504 | Director | 40.6 M of 62.6 M |
||
| Ardelyx Inc | 021-268091 | Director | 110.0 M of 110.0 M |
||
| 3-V Biosciences Inc | 021-266373 | Director | 5.4 M of 12.0 M |
||
| Mersana Therapeutics Inc | 021-265754 | Director | 33.1 M of 33.1 M |
||
| Imara Inc | 021-261834 | Director | 6.0 M of 31.0 M |
||
| Tesaro Inc | 021-261523 | Director | 50.0 M of 50.0 M |
||
| Tesaro Inc | 021-258996 | Director | 155.0 M of 155.0 M |
||
| Ardelyx Inc | 021-242234 | Director | 77.8 M of 108.0 M |
||
| 3-V Biosciences Inc | 021-236101 | Director | 14.3 M of 35.0 M |
||
| Mersana Therapeutics Inc | 021-235062 | Director | 10.1 M of 35.5 M |
||
| Prosensa Holding NV | 021-229654 | Director | 50.5 M of 50.5 M |
||
| Xtuit Pharmaceuticals Inc | 021-229519 | Director | 22.0 M of 22.0 M |
||
| Adaptimmune Ltd | 021-225667 | Director | 103.8 M of 103.8 M |
||
| Mersana Therapeutics Inc | 021-204292 | Executive Officer | 14.5 M of 14.5 M |
||
| Edimer Pharmaceuticals Inc | 021-200941 | Director | 9.8 M of 18.0 M |
||
| 3-V Biosciences Inc | 021-198677 | Director | 7.5 M of 20.4 M |
||
| Cydan LLC | 021-194829 | Director | 6.6 M of 26.3 M |
||
| Omthera Pharmaceuticals Inc | 021-192546 | Director | 17.6 M | ||
| Zyngenia Inc | 021-183742 | Director | 10.0 M of 10.0 M |
||
| Mersana Therapeutics Inc | 021-182471 | Director | 12.5 M of 27.0 M |
||
| NEA 14 Manager Fund LP | 021-177519 | Director | of 12.9 M |
||
| 3-V Biosciences Inc | 021-169863 | Director | 20.1 M of 25.0 M |
||
| Ardelyx Inc | 021-162407 | Director | 17.6 M of 22.3 M |
||
| Tesaro Inc | 021-161614 | Director | 40.0 M of 101.0 M |
||
| Omthera Pharmaceuticals Inc | 021-156702 | Director | 39.0 M of 49.0 M |
||
| Zyngenia Inc | 021-152481 | Director | 5.0 M of 15.0 M |
||
| Ardelyx Inc | 021-151534 | Director | 5.0 M of 10.0 M |
||
| Zosano Pharma Inc | 021-146604 | Director | 3.1 M of 16.0 M |
||
| Tesaro Inc | 021-142327 | Director | 10.0 M of 20.0 M |
||
| Zosano Pharma Inc | 021-110871 | Director | 39.0 M of 39.0 M |
||
| 3-V Biosciences Inc | 021-103158 | Director | 15.0 M of 30.0 M |
||
| Related People Network |
|---|
| Network #118 at NEA Management Company LLC — files alongside 26 co-filers |